2016 Medicinal Chemistry Reviews

Volume 51
Manoj C. Desai, Editor-In-Chief

Medicinal Chemistry Reviews is an outstanding 600 page volume providing timely and critical reviews of important topics in medicinal chemistry. It is provided free of charge to MEDI members in electronic format. 

Members can also order a print copy, for the cost of printing, shipping and handling ($40 to US addresses, $85 international) at our secure e-commerce site.

Members: To access your electronic copy:

--Click 'Member Login' in the upper right corner of this page
--On the Member Login page, click the 'Resources' tab.

Nonmembers, libraries and institutions wishing to purchase a copy may visit our secure e-commerce site and purchase at non-member prices.

You may also purchase electronic copies of individual chapters at our secure e-commerce site.

Table of Contents:

Chapter 1 Lessons From Decades of R&D Management
Chapter 2

Recent Developments in Neuropeptide S Receptor (NPSR) Research

Chapter 3

Metabotropic Glutamate Receptors at Thirty:  New Insights from Chemical Tools

Chapter 4

Small-Molecule Selective PPAR-gamma Modulators

Chapter 5

Nonpeptide AT2 Receptor Agonists

Chapter 6

Recent Developments in Melanin-Concentrating Hormone Receptor 1 Antagonists

Chapter 7

Targeting Necroptosis for Therapeutic Intervention in Inflammatory Diseases

Chapter 8

Recent Advances in the Discovery and Development of Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists

Chapter 9

Small-Molecule Modulators of Protein Arginine Deaminases (PAD)

Chapter 10

Estrogen Receptor Degraders for the Treatment of ER-positive Breast Cancer

Chapter 11

Small-Molecule Modulators of Keap1-Nrf2

Chapter 12

Small-Molecule Modulators Targeting the Unfolded Protein Response Sensor IRE1-alpha

Chapter 13

Approaches to Eradicate HIV Infection

Chapter 14

Therapeutics for Treatment of Ebola and Other Filovirus Infections

Chapter 15

Polymyxins Targeting the Outer Membrane of Gram-Negative Bacteria

Chapter 16

Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease

Chapter 17

Targeting beta-Amyloid and Tau Protein Oligomers and Aggregates as a Novel Approach to the Treatment of Alzheimer's Disease

Chapter 18

Development of VEGFR Inhibitors as Antiangiogenic Agents

Chapter 19

Recent Developments in Chiral Phosphorothioate Oligonucleotides

Chapter 20

Boron in Medicinal Chemistry

Chapter 21

Protein Degraders:  Moving Towards Therapeutically Viable Agents

Chapter 22

Case History:  The Discovery of the First Hepatitis C Virus NS5A Replication Complex Inhibitor Daclatasvir (Daklinza™)

Chapter 23

Case History:  Vorapaxar (Zontivity®):  A First-In-Clas Protease-Activated Receptor-1 (PAR-1) Antagonist Antiplatelet Agent

Chapter 24

New Chemical Entities Entering Phase III Trials in 2015

Chapter 25

To Market, To Market--2015

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org